Journal:Protein Science:2
From Proteopedia
(Difference between revisions)

(One intermediate revision not shown.) | |||
Line 1: | Line 1: | ||
- | <StructureSection load='' size='450' side='right' scene='72/725874/Cv/ | + | <StructureSection load='' size='450' side='right' scene='72/725874/Cv/39' caption=''> |
===The Impact of Crystallization Conditions on Structure-Based Drug Design: a Case Study on the Methylene Blue/Acetylcholinesterase Complex=== | ===The Impact of Crystallization Conditions on Structure-Based Drug Design: a Case Study on the Methylene Blue/Acetylcholinesterase Complex=== | ||
<big>Orly Dym, Wanling Song, Clifford Felder, Esther Roth, Valery Shnyrov, Yacov, Ashani, Yechun Xu, Robbie P. Joosten, Lev Weiner, Joel L. Sussman, and Israel Silman</big> <ref>PMID:26990888</ref> | <big>Orly Dym, Wanling Song, Clifford Felder, Esther Roth, Valery Shnyrov, Yacov, Ashani, Yechun Xu, Robbie P. Joosten, Lev Weiner, Joel L. Sussman, and Israel Silman</big> <ref>PMID:26990888</ref> | ||
<hr/> | <hr/> | ||
<b>Molecular Tour</b><br> | <b>Molecular Tour</b><br> | ||
- | Crystal structure of ''Tc''AChE <scene name='72/725874/Cv/ | + | Crystal structure of ''Tc''AChE <scene name='72/725874/Cv/40'>shows its two subdomains</scene> (<font color='purple'><b>residues 4-305, purple</b></font>, and <font color='red'><b>residues 306-535, red</b></font>). The <scene name='72/725874/Cv/29'>entrance to the active-site gorge</scene> located between the two sub-domains. There are several of the conserved aromatic residues: <scene name='72/725874/Cv/30'>Trp279</scene>, in the peripheral anionic site (PAS) at the top of the gorge; <scene name='72/725874/Cv/31'>Tyr121</scene>, mid-way down the gorge, and <scene name='72/725874/Cv/32'>Trp84</scene>, the principal element of the catalytic ‘anionic’ sub-site (CAS), near the bottom. CAS involves the <scene name='72/725874/Cv/33'>catalytic triad Ser200, His440, and Glu327</scene>. <span style="color:yellow;background-color:black;font-weight:bold;">The carbon atoms of these conserved residues colored yellow</span>. |
Structure-based drug design utilizes experimental 3D apo-protein or complex structures that are usually retrieved from the PDB. Over 57% of the crystallographic PDB entries were obtained with polyethyleneglycols (PEGs) as precipitant and/or as cryoprotectant, but fewer than 6% of | Structure-based drug design utilizes experimental 3D apo-protein or complex structures that are usually retrieved from the PDB. Over 57% of the crystallographic PDB entries were obtained with polyethyleneglycols (PEGs) as precipitant and/or as cryoprotectant, but fewer than 6% of |
Current revision
|
- ↑ Dym O, Song W, Felder C, Roth E, Shnyrov V, Ashani Y, Xu Y, Joosten RP, Weiner L, Sussman JL, Silman I. The Impact of Crystallization Conditions on Structure-Based Drug Design: A Case Study on the Methylene Blue/Acetylcholinesterase Complex. Protein Sci. 2016 Mar 14. doi: 10.1002/pro.2923. PMID:26990888 doi:http://dx.doi.org/10.1002/pro.2923
Proteopedia Page Contributors and Editors (what is this?)
This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.